Vialwirebiotech, curated
September 30, 2026, 1:45 PM
September 2, 2026
- 12:00 PM · BioWorld12:00 PMNovartis taps Alteogen’s ALT-B4 for SC drug delivery in $3B deal — BioWorld
- 12:00 PM · BioWorld12:00 PMMHRA joins EMA in taking Amgen’s Tavneos off the market — BioWorld
- 12:00 PM · BioWorld12:00 PMRoche nabs Simcere’s preclinical trispecific TCE in $1.53B deal — BioWorld
- 11:22 AM · BioPharma Dive11:22 AMUniQure, after setbacks, seeks FDA approval of Huntington’s gene therapy — BioPharma Dive
- 10:12 AM · BioPharma Dive10:12 AMTeva claims success in celiac study; BioMarin, Ascendis settle patent dispute — BioPharma Dive
- 9:00 AM · BioWorld9:00 AMWestlake Laboratory patents new ERK1/2 inhibitors — BioWorld
- 9:00 AM · BioWorld9:00 AMOno and Aitia partner in neurological diseases — BioWorld
- 9:00 AM · BioWorld9:00 AMMerck KGaA’s M-5542 shows promise in autoimmune disease — BioWorld
- 9:00 AM · BioWorld9:00 AMEvotec and Plectonic Biotech collaborate on TCE strategies — BioWorld
- 9:00 AM · BioWorld9:00 AMMira advances IND-enabling studies of MIRA-55 for pain — BioWorld
- 9:00 AM · BioWorld9:00 AMStyx brings Zoencure on board to accelerate ADC pipeline — BioWorld
- 9:00 AM · BioWorld9:00 AMJanssen Pharmaceutica discovers new WRN inhibitors — BioWorld
- 9:00 AM · BioWorld9:00 AMTIE2 inhibitors reported in Haihe Biopharma patent — BioWorld
- 9:00 AM · BioWorld9:00 AMCumulus Oncology patent discloses new GPR68 antagonists — BioWorld
- 9:00 AM · BioWorld9:00 AMDnak Therapeutics uses GATC’s AI platform in candidate evaluation — BioWorld
- 7:00 AM · Drug Discovery World7:00 AMLandmark safety data support therapeutic angiogenesis — Drug Discovery World
- 4:50 AM · Pharmaceutical Technology4:50 AMTakeda and Weave Bio collaborate on AI-driven automation in drug development — Pharmaceutical Technology
September 1, 2026
- 2:30 PM · Nikkei Asia2:30 PMJapan stem cell heart disease patch gets insurance approval — Nikkei Asia
- 12:00 PM · BioWorld12:00 PMInvestors balk at Alumis’ phase IIb subgroup analysis in SLE — BioWorld
- 12:00 PM · BioWorld12:00 PMMicot’s TrkB agonist meets phase II stroke endpoints — BioWorld
- 12:00 PM · BioWorld12:00 PMMOU with FDA to aid SEC’s enforcement across the life sciences — BioWorld
- 12:00 PM · BioWorld12:00 PMPhase III path opens for Ideaya’s IDE-849 in DLL3 ADC horse race — BioWorld
- 12:00 PM · BioWorld12:00 PMHaisco expands newco strategy in $1.5B Sentivera deal — BioWorld
- 12:00 PM · BioWorld12:00 PMExelixis secures Cabometyx exclusivity with patent win — BioWorld
- 11:58 AM · BioPharma Dive11:58 AMNovartis says MS pill succeeds in two large studies — BioPharma Dive
- 9:00 AM · BioWorld9:00 AMHelix Biomedix raises funds for xeroderma pigmentosum program — BioWorld
- 9:00 AM · BioWorld9:00 AMMucolipin-1 activators reported in Libra Therapeutics patent — BioWorld
- 9:00 AM · BioWorld9:00 AMFunding at Amyl Therapeutics advances multi-amyloid immunotherapy — BioWorld
- 9:00 AM · BioWorld9:00 AMAstrazeneca synthesizes new KRAS mutant inhibitors — BioWorld
- 9:00 AM · BioWorld9:00 AMCrinetics Pharmaceuticals discloses GLP-1R agonists — BioWorld
- 9:00 AM · BioWorld9:00 AMConvergen closes seed+ financing round — BioWorld
- 8:00 AM · BioWorld8:00 AMA&As: New posts at Daiichi; Nihon Kohden promotes Zac Ballard — BioWorld
- 8:00 AM · BioWorld8:00 AMFinancings: Kazia's $40M follow-on; Convergen's $15M seed round — BioWorld
- 6:56 AM · Drug Discovery World6:56 AMWhy G‑quadruplex biology is back and what it means for MYC‑driven cancers — Drug Discovery World
- 6:30 AM · SCMP — Tech6:30 AMManus resumes solo operations after collapse of US$2 billion Meta deal — SCMP — Tech
- 5:05 AM · Pharmaceutical Technology5:05 AMPharmaEssentia’s Besremi receives FDA approval for ET — Pharmaceutical Technology
- 4:52 AM · Pharmaceutical Technology4:52 AMKazia closes oversubscribed offering to fund paxalisib’s clinical development — Pharmaceutical Technology
- 4:30 AM · STAT News